Valuation: Biogen Inc.

Market Cap 32.49B 28.87B 26.94B 24.56B 46.31B 3,123B 46.74B 326B 126B 1,597B 122B 119B 5,124B P/E 2026 *
35.9x
P/E 2027 * 19.4x
Enterprise Value 37.42B 33.25B 31.04B 28.29B 53.35B 3,598B 53.85B 376B 146B 1,839B 141B 137B 5,903B EV / Sales 2026 *
3.58x
EV / Sales 2027 * 3.28x
Free-Float
85.8%
Yield 2026 *
-
Yield 2027 * -
1 week+4.39%
1 month+4.85%
3 months+26.31%
6 months+26.31%
Current year+26.31%
1 week 219.07
Extreme 219.07
228.69
1 month 212.29
Extreme 212.29
228.69
Current year 181.06
Extreme 181.06
228.69
1 year 130.24
Extreme 130.24
228.69
3 years 120.74
Extreme 120.74
245
5 years 120.74
Extreme 120.74
318.8
10 years 120.74
Extreme 120.74
410.01
Manager TitleAgeSince
Chief Executive Officer 66 2022-11-13
Director of Finance/CFO 60 2025-02-28
Chief Tech/Sci/R&D Officer - 2024-10-27
Director TitleAgeSince
Director/Board Member 69 2010-03-22
Director/Board Member 77 2009-12-31
Director/Board Member 72 2019-06-18
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.39% - - 32.49B
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.21%-3.39%+27.17%+57.15% 410.8B
Weighted average by Cap. +0.42%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales 10.44B 9.28B 8.66B 7.89B 14.89B 1,004B 15.03B 105B 40.61B 513B 39.21B 38.36B 1,647B 10.66B 9.47B 8.84B 8.06B 15.19B 1,025B 15.33B 107B 41.45B 524B 40.01B 39.15B 1,681B
Net income 997M 886M 827M 753M 1.42B 95.82B 1.43B 10B 3.88B 48.99B 3.74B 3.66B 157B 1.86B 1.65B 1.54B 1.4B 2.65B 179B 2.67B 18.65B 7.23B 91.35B 6.98B 6.83B 293B
Net Debt 4.94B 4.39B 4.09B 3.73B 7.04B 475B 7.1B 49.54B 19.2B 243B 18.53B 18.13B 779B 2.42B 2.15B 2.01B 1.83B 3.45B 233B 3.48B 24.29B 9.41B 119B 9.09B 8.89B 382B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change
26-10-02 US$228.69 0.00%
26-10-01 US$228.69 0.00%
26-09-30 US$228.69 0.00%
26-09-29 US$228.69 +4.39%
26-09-28 US$219.07 0.00%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
219.88USD
Average target price
238.18USD
Spread / Average Target
+8.32%

Quarterly revenue - Rate of surprise